Replies to post #98 on Sana Biotechnology Inc (SANA)

[HANUMAN]

SANA news from 2 weeks ago:
Sana Biotechnology, Inc. (the “Company” or “Sana”) intends to discuss an updated corporate presentation (the “Corporate Presentation”) at the 44th Annual J.P. Morgan
Healthcare Conference on January 14, 2026. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report
Company’s programs and platforms, including the following:
• At 12 months post-transplantation into a patient with type 1 diabetes who received no immunosuppression, UP421, a primary pancreatic islet cell therapy
engineered with Sana’s hypoimmune platform (“HIP”) technology, continued to survive, evade immune detection, and function.
• Sana remains on track to file an investigational new drug application (“IND”) and begin a Phase 1 trial for SC451, a HIP-modified, induced pluripotent stem cell
(“iPSC”)-derived pancreatic islet cell therapy, as early as this year.
• Sana announced its goal of generating initial human data as early as this year for SG293, an in vivo CD19-directed CAR T cell therapy.